cache/8100b579924f0f8db153894c2cf56fd4677df0696992f814014b96246d4be584

COM:SYNOXTHERAPEUTICS

SynOx Therapeutics

  • Privately Held

SynOx Therapeutics is solely focused on developing emactuzumab, a best-in-class monoclonal antibody against CSF-1R, for the treatment of tenosynovial giant cell tumours (TGCT) and other macrophage-driven pathologies. The company's mission is to establish emactuzumab as a best-in-class drug of choice to address unmet needs and improve the quality of life for as many patients as ...Show More

investor of